Seattle Genetics Inc (SGEN)

65.98
1.50 2.20
NASDAQ : Health Care
Prev Close 67.45
Open 67.86
Day Low/High 66.09 / 67.97
52 Wk Low/High 26.02 / 50.67
Volume 243.50K
Avg Volume 694.40K
Exchange NASDAQ
Shares Outstanding 142.72M
Market Cap 9.51B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AOSL, AVD, BCC, BGSF, CDR, CTRE, DV, LUK, PHX, PRLB, RTIX, SFM, STAY, TRP, WAGE, ZAGG Downgrades: ABCO, ACIW, AMAG, CQP, HDNG, INT, NEWM, RGS, SGEN, SSP, TAC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Immunomedics, Seattle Genetics Scrap License Deal

Immunomedics, Seattle Genetics Scrap License Deal

Delaware Vice Chancellor J. Travis Laster in March halted the deal as a result of a lawsuit filed by VenBio Partners, an activist firm invested in Immunomedics.

Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated

Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated

Immunomedics and Seattle Genetics have agreed to terminate the license pact that was first announced in February.

Seattle Genetics Terminates License Agreement With Immunomedics For Sacituzumab Govitecan (IMMU-132)

Seattle Genetics Terminates License Agreement With Immunomedics For Sacituzumab Govitecan (IMMU-132)

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it has agreed to terminate its license agreement with Immunomedics, Inc.

Seattle Genetics Reports First Quarter 2017 Financial Results

Seattle Genetics Reports First Quarter 2017 Financial Results

Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today reported financial results for the first quarter ended March 31, 2017.

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter Financial Results On April 27, 2017

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter Financial Results On April 27, 2017

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter financial results on Thursday, April 27, 2017, after the close of financial markets.

Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate And Novel Immuno-Oncology Programs At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate And Novel Immuno-Oncology Programs At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today highlighted multiple data presentations that support the company's advancing antibody-drug conjugate (ADC) and immuno-oncology programs at...

Seattle Genetics Highlights Leadership In Antibody-Drug Conjugate Technology Innovation At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics Highlights Leadership In Antibody-Drug Conjugate Technology Innovation At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced its broad presence at the upcoming 108 th Annual Meeting of the American Association for Cancer Research (AACR) being held April...

12 Years and Still Finding the Bulls for You: Cramer's 'Mad Money' Recap (Tuesday 3/14/17)

12 Years and Still Finding the Bulls for You: Cramer's 'Mad Money' Recap (Tuesday 3/14/17)

Jim Cramer says it's his job to educate and entertain you, as well as help you make and save money.

Cisco Systems, CyberArk, Check Point Software: 'Mad Money' Lightning Round

Cisco Systems, CyberArk, Check Point Software: 'Mad Money' Lightning Round

Jim Cramer is bullish on Cisco Systems, Check Point Software and CyberArk Software.

Immunomedics Soars on Injunction Against Seattle Genetics Deal

Immunomedics Soars on Injunction Against Seattle Genetics Deal

The biotech company embattled by activist investor VenBio may not be able to go through with its licensing deal.

FDA Lifts Clinical Hold On Seattle Genetics' Phase 1 Trials Of Vadastuximab Talirine

FDA Lifts Clinical Hold On Seattle Genetics' Phase 1 Trials Of Vadastuximab Talirine

Seattle Genetics, Inc. (Nasdaq:SGEN), a global biotechnology company, today announced that the U.

Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote

Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote

The newly reconstituted Immunomedics board is likely to start a search for a new CEO and could either renegotiate the IMMU-132 deal with Seattle Genetics or cancel it.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Seattle Genetics Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 13, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Seattle Genetics Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 13, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc.

Seattle Genetics To Present At Upcoming Investor Conferences

Seattle Genetics To Present At Upcoming Investor Conferences

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences.

SGEN SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Seattle Genetics Inc. And A Lead Plaintiff Deadline Of March 13, 2017

SGEN SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Seattle Genetics Inc. And A Lead Plaintiff Deadline Of March 13, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased Seattle Genetics Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Seattle Genetics Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 13, 2017 - SGEN

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Seattle Genetics Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 13, 2017 - SGEN

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc.

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf...

Activist Investor to Block Partnership of Immunomedics and Seattle Genetics

Activist Investor to Block Partnership of Immunomedics and Seattle Genetics

The largest shareholder of Immunomedics, VenBio, asks for an injunction against its partnership with Seattle Genetics.

Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics

Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics

VenBio accuses Immunomedics management of undervaluing and essentially giving away the cancer drug IMMU-132 because they were afraid of losing their jobs in a proxy vote.

SGEN SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Seattle Genetics Inc. And A Lead Plaintiff Deadline Of March 13, 2017

SGEN SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Seattle Genetics Inc. And A Lead Plaintiff Deadline Of March 13, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased Seattle Genetics Inc.

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Sage Therapeutics, Immunomedics and Myriad Genetics were among the premarket biotech stock movers on Monday.

Seattle Genetics To Present At Leerink Partners 6th Annual Global Healthcare Conference

Seattle Genetics To Present At Leerink Partners 6th Annual Global Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15 at 2:30pm Eastern Time.

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.